Last update 01 Nov 2024

Zhejiang Fukang Pharmaceutical Co., Ltd.

Private Company|
2022|
Zhejiang Sheng, China

Overview

Tags

Congenital Disorders
Immune System Diseases
Digestive System Disorders
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases1
Immune System Diseases1
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
PI3Kβ x PI3Kδ1

Related

3
Drugs associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
Neratinib maleate
Target
EGFR x HER2 x HER4
Mechanism
EGFR antagonists [+2]
Active Org.
Convalife (Shanghai) Co. Ltd.Convalife (Shanghai) Co. Ltd. [+10]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Early Stage Breast Carcinoma [+25]
Inactive Indication
Advanced HER2-Positive Breast Carcinoma [+11]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date17 Jul 2017
KA-2237
Target
PI3Kβ x PI3Kδ
Mechanism
PI3Kβ inhibitors [+1]
Active Org.
Zhejiang Fukang Pharmaceutical Co., Ltd. [+1]
Originator Org.
Kareus Therapeutics SA
Active Indication
Activated PI3K-delta Syndrome [+11]
Inactive Indication
B-Cell Lymphoma [+1]
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
CVL-006
Target-
Mechanism-
Active Org.
Convalife (Shanghai) Co. Ltd.Convalife (Shanghai) Co. Ltd. [+1]
Originator Org.
Convalife (Shanghai) Co. Ltd.Convalife (Shanghai) Co. Ltd.
Active Indication
Advanced Malignant Solid Neoplasm
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
CTR20240229 / Not yet recruitingPhase 2
CVL237 片治疗 PTEN 缺失的晚期实体瘤的单臂、开放、多中心、II 期临床研究
[Translation] A single-arm, open-label, multicenter, phase II clinical study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency
100 Clinical Results associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Approval
2
1
Phase 2 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
KA-2237
 ( PI3Kβ x PI3Kδ )		Prostatic Cancer
More
Phase 2
Neratinib maleate
 ( EGFR x HER2 x HER4 )		HER2 Positive Solid Tumors
More
IND Approval
CVL-006
Advanced Malignant Solid Neoplasm
More
IND Approval
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free